<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387500</url>
  </required_header>
  <id_info>
    <org_study_id>20190813</org_study_id>
    <nct_id>NCT04387500</nct_id>
  </id_info>
  <brief_title>Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma</brief_title>
  <official_title>Single-arm Phase II Clinical Trial to Evaluate the Initial Efficacy and Safety of Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of
      Sintilimab injection combined with Inlyta in fumarate hydratase-deficient renal cell
      carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our previous genetic research as well as other published data indicated the possible well
      response to combination of immunotherapy with targeted therapy in FH-deficient renal cell
      carcinoma, therefore we intented to perform this single-arm phase II clinical trial to
      evaluate the initial efficacy and safety of Sintilimab injection combined with Inlyta in
      FH-deficient renal cell carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>3 years</time_frame>
    <description>progression-free survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>3 years</time_frame>
    <description>objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>life quality</measure>
    <time_frame>3 years</time_frame>
    <description>evaluate life quality using EuroQol-5D utility score (EQ-5D index) and the EQ-5D visual analogue scale (EQ-VAS) responses</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, also types and degree</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <condition>Fumarate Hydratase Deficiency</condition>
  <condition>Immunotherapy</condition>
  <arm_group>
    <arm_group_label>Sintilimab injection combined with Inlyta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sintilimab injection 10ml: 100mg, 200mg intravenously, once every three weeks. Course of treatment: discontinue medication when the disease progresses clinically or radiologically.
Inlyta 5mg orally, twice a day. Course of treatment: continue treatment as long as a clinical benefit is observed, or until an unacceptable toxicity is present that cannot be controlled by combination or dose adjustment.
In the whole research process, if the disease progresses, the attending doctor has the right to carefully choose other anti-tumor methods, including radiotherapy, chemotherapy and other targeted drugs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab injection</intervention_name>
    <description>Combined Sintilimab injection and Inlyta treatment in FH-deficient RCC</description>
    <arm_group_label>Sintilimab injection combined with Inlyta</arm_group_label>
    <other_name>Inlyta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age ≥ 18;

          2. histology characteristics accord with FH-deficient RCC;

          3. gene testing confirms germline and/or somatic FH gene mutation ;

          4. ECOG (Eastern Cooperative Oncology Group)≤2;

          5. expected survival &gt;3 months;

          6. blood routine indexes: neutrophils ≥1.5*109, platelets ≥100*109, hemoglobin ≥90g/L;

          7. liver function: bilirubin ≤ normal upper limit 1.5 times, AST≤ normal upper limit 2.5
             times;Serum creatinine ≤ 1.5 times of normal upper limit;Serum calcium concentration:
             ≤12.0 mg/dL;

          8. coagulation function: PT≤ 1.5 times of normal upper limit;

          9. the following diseases did not appear within 12 months: myocardial infarction, severe
             or unstable angina pectoris, asymptomatic heart failure, cardiovascular and
             cerebrovascular accident or transient ischemic attack, etc.

         10. all patients signed informed consent.

        Exclusion Criteria:

          1. other malignancies previously or at the same time that are different from the primary
             site or histology of the tumor assessed in this study, except cervical carcinoma in
             situ, basal-cell carcinoma that has been fully treated, superficial bladder tumor (Ta,
             Tis, T1) or other malignancies that occurred before the enrollment and have been cured
             for more than 3 years;

          2. renal decompensation requires hemodialysis or peritoneal dialysis;

          3. arrhythmia need anti-arrhythmic treatment, symptomatic coronary artery disease or
             myocardial ischemia (myocardial infarction), nearly six months, or congestive heart
             failure than NYHA Ⅱ level; Hypertension (systolic blood pressure &gt;160 mmHg or
             diastolic blood pressure &gt;100 mmHg) that has been treated with 2 or more
             antihypertensive treatments and still cannot be controlled;

          4. severe active clinical infection;

          5. patients with coagulation disorder or bleeding constitution;

          6. major surgery or severe trauma was performed within 4 weeks before enrollment;

          7. a history of allogeneic organ transplantation or bone marrow transplantation;

          8. drug abuse and medical, psychological or social conditions that may interfere with
             patients' participation in research or affect the evaluation of results;

          9. known or suspected allergy to the study drug;

         10. those who received treatment other than this study within 4 weeks prior to and during
             the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hao Zeng</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hao Zeng, Doctor</last_name>
    <phone>8618980602129</phone>
    <email>kucaizeng@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guangxi Sun, Doctor</last_name>
      <phone>8613258287587</phone>
      <email>sungx077@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomäki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen LA; Multiple Leiomyoma Consortium. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002 Apr;30(4):406-10. Epub 2002 Feb 25.</citation>
    <PMID>11865300</PMID>
  </reference>
  <reference>
    <citation>Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005 Aug;8(2):143-53.</citation>
    <PMID>16098467</PMID>
  </reference>
  <reference>
    <citation>Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS, DeBerardinis RJ. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2011 Nov 20;481(7381):385-8. doi: 10.1038/nature10642.</citation>
    <PMID>22101431</PMID>
  </reference>
  <reference>
    <citation>Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, Min BW, Tan MH, Zhang Z, Yang XJ, Zhou M, Gardie B, Molinié V, Richard S, Tan PH, Teh BT, Furge KA. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell. 2011 Oct 18;20(4):511-23. doi: 10.1016/j.ccr.2011.08.024.</citation>
    <PMID>22014576</PMID>
  </reference>
  <reference>
    <citation>Voss MH, Molina AM, Chen YB, Woo KM, Chaim JL, Coskey DT, Redzematovic A, Wang P, Lee W, Selcuklu SD, Lee CH, Berger MF, Tickoo SK, Reuter VE, Patil S, Hsieh JJ, Motzer RJ, Feldman DR. Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2016 Nov 10;34(32):3846-3853. doi: 10.1200/JCO.2016.67.9084.</citation>
    <PMID>27601542</PMID>
  </reference>
  <reference>
    <citation>Kusmartsev S, Eruslanov E, Kübler H, Tseng T, Sakai Y, Su Z, Kaliberov S, Heiser A, Rosser C, Dahm P, Siemann D, Vieweg J. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol. 2008 Jul 1;181(1):346-53.</citation>
    <PMID>18566400</PMID>
  </reference>
  <reference>
    <citation>Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, Denker M, Leveque V, Cañamero M, Babitski G, Koeppen H, Ziai J, Sharma N, Gaire F, Chen DS, Waterkamp D, Hegde PS, McDermott DF. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016 Aug 30;7:12624. doi: 10.1038/ncomms12624.</citation>
    <PMID>27571927</PMID>
  </reference>
  <reference>
    <citation>Najjar YG, Rayman P, Jia X, Pavicic PG Jr, Rini BI, Tannenbaum C, Ko J, Haywood S, Cohen P, Hamilton T, Diaz-Montero CM, Finke J. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α. Clin Cancer Res. 2017 May 1;23(9):2346-2355. doi: 10.1158/1078-0432.CCR-15-1823. Epub 2016 Oct 31.</citation>
    <PMID>27799249</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>May 9, 2020</last_update_submitted>
  <last_update_submitted_qc>May 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Hao Zeng</investigator_full_name>
    <investigator_title>Professor of Department of Urology</investigator_title>
  </responsible_party>
  <keyword>Sintilimab</keyword>
  <keyword>Inlyta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>There is a plan to make IPD and related data dictionaries available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data would be available starting from the time when summary data are published or otherwise made available, for 3 years.</ipd_time_frame>
    <ipd_access_criteria>Other researchers access the data by sending an email to our PI.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT04387500/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

